PepsRadar
⌕ Search✧ Ask
Both are experimental, once-weekly weight-loss drugs that act on amylin receptors (a fullness-hormone pathway) rather than GLP-1, and neither is approved. Eloralintide, from Eli Lilly, was designed to prefer one amylin receptor, AMY1; cagrilintide, from Novo Nordisk, acts broadly across amylin and calcitonin receptors and is furthest along as part of the combination CagriSema.
2:45Video overview · 2:45
How the amylin fullness hormone works, what the 48-week phase 2 trial found, the side effects, how it differs from cagrilintide, the phase 3 trials under way, and why it is not approved.
Narrated with an AI voice from this page's sources; education only, no dosing. Watch on YouTube ↗
| Fact | Eloralintide | Cagrilintide |
|---|---|---|
| FDA status | Not FDA-approved | Not FDA-approved |
| What it is | Eloralintide is an experimental weight-loss drug from Eli Lilly that acts on amylin receptors instead of the GLP-1 receptor used by semaglutide and tirzepatide. In a 48-week phase 2 trial, average weight loss ranged from about 9% to 20% across dose groups, versus 0.4% on placebo. It is not approved, and phase 3 trials began in 2025 and 2026. | Cagrilintide is an amylin analogue investigated for weight management. Its evidence must be separated from evidence for combinations containing it. |
| Human evidence | 1 randomized trial | 3 randomized trials |
| Human safety data | Trials only. Eloralintide is an investigational amylin-receptor drug. In trials, nausea and fatigue were the most common side effects; long-term safety and rare harms are not yet known. | Trials only. Cagrilintide is an investigational amylin analogue. In trials, digestive side effects and injection-site reactions were common; long-term safety and rare harms are not yet known. |
| Boxed warning | No FDA label to carry one | No FDA label to carry one |
| Serious risks | None listed | None listed |
| Conditions flagged | None flagged | None flagged |
| Claim check | No claim check yet | No claim check yet |
Each row comes from the Eloralintide and Cagrilintide profiles, where every fact links to its source. “Conditions flagged” lists the health conditions each profile’s Risks & interactions section mentions.
Human randomized phase 2 trial · 263 adults aged 18 to 75 at 46 US research centers with a BMI of 30 or more, or 27 or more with at least one weight-related condition, and without type 2 diabetes. Mean body weight 109 kg; 78% women.
Average weight change at 48 weeks ranged from about -9% in the lowest dose group to about -20% in the highest groups, versus -0.4% with placebo, and weight loss rose with dose. The most common side effects were nausea (11% to 64% across dose groups, versus 14% with placebo) and fatigue (0% to 46%, versus 12%); both were more common in the higher dose groups than in the lowest ones, though not in a steady pattern.
Limitation: One 48-week phase 2 trial of 263 people, run and funded by the manufacturer. It does not show effects on heart disease, long-term safety or whether the weight stays off, and it did not compare eloralintide with GLP-1 drugs or with cagrilintide. Phase 3 results are not expected until about 2028.
Human phase 2 randomized trial · 706 adults with obesity, or overweight with hypertension or dyslipidemia, without diabetes.
Estimated mean weight reduction ranged from 6.0% to 10.8% across cagrilintide groups versus 3.0% with placebo in the trial-product analysis. Gastrointestinal and injection-site events were frequent.
Limitation: This is monotherapy evidence. It cannot be presented as the result for CagriSema or for an unidentified seller blend; longer-term outcomes require separate studies.
Human phase 3 randomized trial · 3,417 adults with obesity, or overweight with an obesity-related complication, without diabetes.
Estimated weight change was −20.4% with the combination versus −3.0% with placebo under the treatment-policy analysis. Gastrointestinal events occurred in 79.6% versus 39.9%.
Limitation: The analysis includes treatment discontinuation. Different estimands can produce different headlines. It does not establish long-term cardiovascular benefit or equivalence to a seller blend. Funded by Novo Nordisk.
Human phase 3 randomized trial · 1,206 adults with type 2 diabetes and BMI of at least 27.
Estimated weight change was −13.7% versus −3.4%. HbA1c of 6.5% or lower was reached by 73.5% versus 15.9%. Gastrointestinal events occurred in 72.5% versus 34.4%.
Limitation: Without separate component arms, this trial cannot isolate cagrilintide’s contribution. Weight and glucose endpoints do not prove longer survival or validate research-use mixtures. Funded by Novo Nordisk.
Results from different trials are not a head-to-head comparison: the people, preparations, durations and measures differ.
Two drugs testing the same idea from different angles, with no head-to-head trial. Vials sold online as either one are not the drugs tested in these trials, and PepsRadar does not list them.
PepsRadar does not give doses or usage instructions, and this page is not medical advice. For a prescription medicine, talk to your prescriber or pharmacist.
Other comparisons: BPC-157 vs TB-500 · Semaglutide vs Tirzepatide · Tirzepatide vs Retatrutide · CJC-1295 vs Ipamorelin · Sermorelin vs Tesamorelin · Selank vs Semax · MOTS-c vs Elamipretide · Ipamorelin vs MK-677 · AOD-9604 vs HGH Fragment 176-191 · Thymosin alpha-1 vs Thymosin beta-4 · Tesamorelin vs CJC-1295 · GHK-Cu vs AHK-Cu · Epitalon vs Pinealon
See something wrong on this page? Report a mistake · Corrections